Compare IMVT & PFSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | IMVT | PFSI |
|---|---|---|
| Founded | 2018 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.8B | 4.7B |
| IPO Year | 2019 | 2018 |
| Metric | IMVT | PFSI |
|---|---|---|
| Price | $33.39 | $86.82 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 8 | 9 |
| Target Price | $33.00 | ★ $128.11 |
| AVG Volume (30 Days) | ★ 2.3M | 485.4K |
| Earning Date | 05-28-2026 | 05-05-2026 |
| Dividend Yield | N/A | ★ 1.35% |
| EPS Growth | N/A | ★ 59.25 |
| EPS | N/A | ★ 1.53 |
| Revenue | N/A | ★ $984,629,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $16.96 |
| P/E Ratio | ★ N/A | $56.45 |
| Revenue Growth | N/A | ★ 3.05 |
| 52 Week Low | $14.09 | $82.65 |
| 52 Week High | $36.29 | $160.36 |
| Indicator | IMVT | PFSI |
|---|---|---|
| Relative Strength Index (RSI) | 63.49 | 45.23 |
| Support Level | $22.84 | $85.27 |
| Resistance Level | N/A | $88.65 |
| Average True Range (ATR) | 1.94 | 2.21 |
| MACD | 0.54 | -0.07 |
| Stochastic Oscillator | 72.62 | 43.03 |
Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The company operates in a single operating segment, which includes all activities related to the research, development and manufacturing of its product candidates.
PennyMac Financial Services Inc is a specialty financial services firm with a comprehensive mortgage platform mainly focused on the production and servicing of U.S. residential mortgage loans. The firm is also engaged in managing investments related to the U.S. mortgage market and provides products and services that leverage technologies to support customers. The company operates through two reportable operating segments: production and servicing. The production segment performs loan origination, acquisition, and sale activities, while the servicing segment performs servicing and subservicing of loans, early buyout transactions, and servicing of loans sourced and managed for PMT. The majority of revenue comes from the production segment.